No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ORGO Organogenesis
- 3.020
- +0.120+4.14%
Close Jul 22 16:00 ET
- 2.870
- -0.150-4.97%
Post 17:46 ET
400.37MMarket Cap75.50P/E (TTM)
3.050High2.870Low329.54KVolume2.910Open2.900Pre Close989.27KTurnover0.53%Turnover Ratio75.50P/E (Static)132.57MShares4.70552wk High1.44P/B186.35MFloat Cap1.96052wk Low--Dividend TTM61.70MShs Float310.900Historical High--Div YieldTTM6.21%Amplitude1.795Historical Low3.001Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Organogenesis Holdings Inc. (ORGO): Is It Among the Best NASDAQ Penny Stocks to Invest In Now?
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
CANTON, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions
Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Stock Is Going Strong: Have Financials A Role To Play?
Is Organogenesis a Hidden Gem in the Biotech Sector?
Lake Street Initiates Organogenesis(ORGO.US) With Buy Rating, Announces Target Price $5
Lake Street analyst Brooks O'Neil initiates coverage on $Organogenesis(ORGO.US)$ with a buy rating, and sets the target price at $5.According to TipRanks data, the analyst has a success rate of 43.3%
Organogenesis Holdings Initiated at Buy by Lake Street
Organogenesis Holdings Initiated at Buy by Lake Street
Comments
$Organogenesis(ORGO.US$ revenue of $110.0 million for the first quarter of 2024, an increase
of $2.3 million compared to net revenue of $107.6 million for the first
quarter of 2023. Net revenue for the first quarter of 2024 consists of:
-- Net revenue from Advanced Wound Care products of $103.9 million,
an increase of 3% from the first quarter of 2023.
-- Net revenue from Surgical & Sports Medicine products of $6.1
million, a decrease of 9% from the first quarter of 2023.
-- Net loss of ...
of $2.3 million compared to net revenue of $107.6 million for the first
quarter of 2023. Net revenue for the first quarter of 2024 consists of:
-- Net revenue from Advanced Wound Care products of $103.9 million,
an increase of 3% from the first quarter of 2023.
-- Net revenue from Surgical & Sports Medicine products of $6.1
million, a decrease of 9% from the first quarter of 2023.
-- Net loss of ...
The implications of ReNu’s success extend far beyond symptom management.
Organogenesis Holdings Inc., a frontrunner in the regenerative medicine landscape, has recently shared groundbreaking results from its Phase 3 clinical trial for ReNu®, a cutting-edge therapy designed for knee osteoarthritis (OA) management. The trial's positive top line data underscore a pivotal moment in pain management and regen...
Organogenesis Holdings Inc., a frontrunner in the regenerative medicine landscape, has recently shared groundbreaking results from its Phase 3 clinical trial for ReNu®, a cutting-edge therapy designed for knee osteoarthritis (OA) management. The trial's positive top line data underscore a pivotal moment in pain management and regen...
$Organogenesis(ORGO.US$
NEWS
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
Organogenesis announced positive top-line data from its Phase 3 clinical trial of ReNu for knee osteoarthritis, achieving a statistically significant reduction in knee pain and maintenance of function at six months. The results open a transformative opportunity for Organogenesis to enter the pain management market. ReNu addresses a critical unmet medical need for knee ...
NEWS
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis
Organogenesis announced positive top-line data from its Phase 3 clinical trial of ReNu for knee osteoarthritis, achieving a statistically significant reduction in knee pain and maintenance of function at six months. The results open a transformative opportunity for Organogenesis to enter the pain management market. ReNu addresses a critical unmet medical need for knee ...
1
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg